ArticleOcular oncology and pathology2017
Growth of Uveal Melanoma following Intravitreal Bevacizumab.
Article in Ocular oncology and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The role of vascular mimicry as a biomarker in malignant melanoma: a systematic review and meta-analysis.BMC cancer · 2019Pooled it
- Erianin Abrogates Cancerous Vasculogenic Mimicry Through Targeting m5C Methylase NSUN2 in Uveal Melanoma.Investigative ophthalmology & visual science · 2025Article
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma.Cancer reports (Hoboken, N.J.) · 2025Review
- A Brief Overview of Uveal Melanoma Treatment Methods with a Focus on the Latest Advances.Journal of clinical medicine · 2025Article
- Current Therapies and Potential Strategies for Uveal Melanoma.Drugs and drug candidates · 2025Article
- PDGFR-α shRNA-polyplex for uveal melanoma treatment via EMT mediated vasculogenic mimicry interfering.Journal of nanobiotechnology · 2024Article
- Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior.Investigative ophthalmology & visual science · 2024Article
- Biological characteristics and clinical management of uveal and conjunctival melanoma.Oncology research · 2024Review
- An immunotherapeutic artificial vitreous body hydrogel to control choroidal melanoma and preserve vision after vitrectomy.Science advances · 2023Article
- Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies.Cancers · 2022Review
- Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Rapid growth of primary uveal melanoma following intravitreal bevacizumab injection: a case report and review of the literature.Digital journal of ophthalmology : DJO · 2021Review
- Vasculogenic Mimicry Formation Predicts Tumor Progression in Oligodendroglioma.Pathology oncology research : POR · 2021Article
- Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma.Life (Basel, Switzerland) · 2020Article
- Article
- Review
- Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.BMC ophthalmology · 2019Article
- TRPM8 Activation via 3-Iodothyronamine Blunts VEGF-Induced Transactivation of TRPV1 in Human Uveal Melanoma Cells.Frontiers in pharmacology · 2018Article
- Five-Year Follow-up of Microincisional Vitrectomy Surgery, Endolaser Tumor Ablation, and Gene-Expression Profiling in Small Uveal Melanoma.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
purposeTypically treatment of large melanomas (by Collaborative Ocular Melanoma Study criteria) is restricted to enucleation, due to size constraints for plaque brachytherapy. Because primary and metastatic uveal melanoma cells are inhibited by bevacizumab (an anti-vascular endothelial growth factor), this prospective study evaluated the impact of intravitreal bevacizumab on large uveal melanomas that were destined for enucleation. Size reduction by bevacizumab would potentially salvage these eyes by making them eligible for treatment with plaque brachytherapy. PROCEDURES: Two patients with large uveal melanoma were each treated with one intravitreous injection of bevacizumab (1.25 mg/0.05 mL).
resultsBoth tumors displayed paradoxical growth 1 week following the injection, with confirmed growth 1 week later (increase from baseline of 1.1 mm in one eye and 3.1 mm in the other eye). Both eyes were enucleated and monosomy 3 and vasculogenic mimicry patterns were identified in both tumors. At 9 years follow-up, both patients were alive and metastasis free.
conclusionThese patients demonstrate that neoadjuvant intravitreous bevacizumab does not decrease the size of large uveal melanomas and may, in fact, result in their paradoxical growth. This observation supports a cautious approach in the use of intravitreous bevacizumab for uveal melanoma, particularly in the neoadjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.